Takeda reported that zasocitinib met co‑primary and key secondary endpoints in two large Phase 3 studies for plaque psoriasis, delivering clear or almost clear skin for more than half of treated patients at four months. The oral TYK2 inhibitor came to Takeda via a $4 billion acquisition and will be positioned as an oral alternative to injectable biologics. The company cited safety and efficacy signals and said it plans regulatory submissions in the U.S. and other markets during fiscal 2026. Takeda is also running head‑to‑head studies versus Bristol Myers Squibb’s Sotyktu and is evaluating zasocitinib in multiple inflammatory indications. The outcome validates Takeda’s large acquisition bet and underscores competition among oral kinase inhibitors for autoimmune diseases; forthcoming full datasets and long‑term safety will determine positioning versus existing therapies.